AU2002230890A1 - Targeted enzyme prodrug therapy - Google Patents
Targeted enzyme prodrug therapyInfo
- Publication number
- AU2002230890A1 AU2002230890A1 AU2002230890A AU3089002A AU2002230890A1 AU 2002230890 A1 AU2002230890 A1 AU 2002230890A1 AU 2002230890 A AU2002230890 A AU 2002230890A AU 3089002 A AU3089002 A AU 3089002A AU 2002230890 A1 AU2002230890 A1 AU 2002230890A1
- Authority
- AU
- Australia
- Prior art keywords
- prodrug therapy
- enzyme prodrug
- targeted enzyme
- targeted
- therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
- A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/86—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides, e.g. penicillinase (3.5.2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nanotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Immunology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60/000,000 | 2000-09-15 | ||
US25577400P | 2000-12-14 | 2000-12-14 | |
US60/255,774 | 2000-12-14 | ||
US27960901P | 2001-03-28 | 2001-03-28 | |
US60/279,609 | 2001-03-28 | ||
PCT/US2001/048529 WO2002047717A2 (en) | 2000-12-14 | 2001-12-14 | Targeted enzyme prodrug therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2002230890A1 true AU2002230890A1 (en) | 2002-06-24 |
Family
ID=26944947
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002230889A Abandoned AU2002230889A1 (en) | 2000-12-14 | 2001-12-14 | Target enzymes |
AU2002230890A Abandoned AU2002230890A1 (en) | 2000-12-14 | 2001-12-14 | Targeted enzyme prodrug therapy |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002230889A Abandoned AU2002230889A1 (en) | 2000-12-14 | 2001-12-14 | Target enzymes |
Country Status (2)
Country | Link |
---|---|
AU (2) | AU2002230889A1 (en) |
WO (2) | WO2002048372A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050164308A1 (en) * | 2003-12-18 | 2005-07-28 | Fiona Harding | Beta-lactamase CD4+ T-cell epitopes |
EP1735350B1 (en) | 2004-04-15 | 2010-08-25 | Genencor International, Inc. | Anti-cea scfv - beta-lactamase constructs (cab molecules) in adept |
ITBG20120050A1 (en) * | 2012-10-29 | 2013-01-28 | Michele Mutti | FUSION PROTEIN WITH PROTEASIC ACTIVITY AND SPECIFICITY OF ANTIBODIES |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1360500B1 (en) * | 2000-04-14 | 2010-01-13 | Genencor International, Inc. | Methods for selective targeting |
-
2001
- 2001-12-14 WO PCT/US2001/048528 patent/WO2002048372A2/en active Search and Examination
- 2001-12-14 AU AU2002230889A patent/AU2002230889A1/en not_active Abandoned
- 2001-12-14 AU AU2002230890A patent/AU2002230890A1/en not_active Abandoned
- 2001-12-14 WO PCT/US2001/048529 patent/WO2002047717A2/en active Search and Examination
Also Published As
Publication number | Publication date |
---|---|
WO2002047717A3 (en) | 2003-03-13 |
WO2002047717A2 (en) | 2002-06-20 |
AU2002230889A1 (en) | 2002-06-24 |
WO2002048372A2 (en) | 2002-06-20 |
WO2002048372A3 (en) | 2003-05-30 |
WO2002047717A9 (en) | 2003-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001252135A1 (en) | Therapeutic agents | |
AU7068600A (en) | Encrypted coupons | |
AU2002223827A1 (en) | Well treatment | |
AUPQ899700A0 (en) | Probiotic recolonisation therapy | |
AU2001267333A1 (en) | Lipolytic enzyme | |
AU2003249679A1 (en) | Anaerobe targeted enzyme-mediated prodrug therapy | |
AU3818300A (en) | Treating hair by targeting enzymes | |
AU2002210463A1 (en) | Transdermal therapeutic system | |
AU2001291783A1 (en) | Encryption | |
AU4430701A (en) | Compounds for targeting | |
AU2001245987A1 (en) | Compositions and methods for gene therapy | |
AU2001263208A1 (en) | Targeting fixture | |
AU2000263864A1 (en) | Tissue specific prodrug | |
AU7737300A (en) | Dna-cleaving rnase p rna | |
AU2001243515A1 (en) | Combination drug therapy | |
AU6522400A (en) | Targeted thrombolytic agents | |
AU2002334891A1 (en) | Tumor targeted photodiagnostic-phototherapeutic agents | |
AU2002335667A1 (en) | Modified reoviral therapy | |
AU2002210379A1 (en) | Subtilase variants | |
AU2001264247A1 (en) | GASC1 gene | |
AU2001236929A1 (en) | Surface treatment | |
AU2001240103A1 (en) | Reproduction-specific genes | |
AU2001273903A1 (en) | Therapeutic agents | |
GB0011060D0 (en) | Improvements relating to gene directed enzyme prodrug therapy | |
AU2001247444A1 (en) | Erbeta-mediated gene expression |